Director/PDMR Shareholding

30 April 2010

Ark Therapeutics Group plc

Transaction by Person Discharging Managerial Responsibilities

Disclosure Rules DTR 3.1.4R

Ark Therapeutics Group plc (LSE: AKT) ("Ark" or the "Company") announces that it was informed on 23 April 2010 that Dr Nigel Parker, CEO, exercised options over 260,000 ordinary Ark shares of 1 pence each on 23 April 2010 in London at an exercise price of 0.0001 pence per share. The option, which was granted to Dr Parker in April 2000, was due to expire on 25 April 2010, if not exercised before then. These shares represent approximately 0.12% of the Company's issued share capital. Following the purchase of these shares, Dr Parker will own 3,154,579 ordinary Ark shares, representing 1.51% of the Company's issued share capital.

Martyn Williams

Company Secretary

Ark Therapeutics Group plc